ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Eligible participants were randomized to 24 weeks multiple daily injection therapy using either the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor or the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be 18 years of age or older.
Diagnosed with Type 1 or Type 2 diabetes.
Recent HbA1c \> 7.5% (measured within the last 6 weeks at local laboratory).
On multiple daily injection (MDI) therapy for at least 6 months consisting of 1-2 injections per day of long-acting basal insulin (Lantus® or Detemir®) and at least 2 injections per day of regular or rapid-acting analog insulin for meal coverage.
Subject adjusts meal insulin doses based on carbohydrate content of meals.
Subject with Type 2 diabetes may be on stable metformin therapy (therapy unchanged during 3 months prior to study).
Subject has been in Investigator's practice for at least 3 months but may have been seen by another physician in the practice.
Subject has completed carbohydrate (CHO) training within the last 2 years.
You may not be if
Subject is on a therapy regimen that conflicts with the study:
* Neutral protamine Hagedorn (NPH) or pre-mixed insulin;
* oral anti-diabetic agents, with the exception of metformin;
* injectable anti-diabetic agents other than long-acting insulin and rapid-acting insulin analogs or regular insulin (eg, fixed dose therapy);
* use of sliding scale insulin therapy that determines insulin dosages based exclusively on specific blood glucose (bG) results.
Subject has participated in another interventional trial within 6 weeks prior to study.
Subject has been diagnosed with any clinically significant infectious disease or major organ system disease, such as gastroparesis or renal disease (at Investigator's discretion).
Subject has used systemic oral or inhaled steroids for more than 7 days within the last 3 months.
Subject is on chemotherapy or radiation therapy (self-reported).
Subject is pregnant or lactating or is currently planning a pregnancy.
Clareo Health | ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
